AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04777370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic manipulation
Description: Individuals will then undergo a single supine grade V thrust manipulation. All manipulations will take place at the T3-4 segment. If a cavitation (pop) is not heard or felt by either the subject or examiner, a second thrust will be performed.
Study NCT05505240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory analysis at cold temperature
Description: Respiratory analysis at an ambient temperature of 18°C
Study NCT05505240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory analysis at room temperature
Description: Respiratory analysis at an ambient temperature of 22°C
Study NCT05505240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory analysis at thermoneutral temperature
Description: Respiratory analysis at an ambient temperature of 28°C
Study NCT05505240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory analysis at hot temperature
Description: Respiratory analysis at an ambient temperature of 38°C
Study NCT05445453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Museum visit
Description: The intervention is a visit of the MMFA. This visit can be done alone or accompanied.~The visit of the MMFA is free for the patient.
Study NCT05698576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)
Description: A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.
Study NCT05742334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation
Description: The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
Study NCT05742334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLG-COMPLETE Allograft Implantation
Description: The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
Study NCT05586477 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
Study NCT05586477 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diphenhydramine
Description: Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
Study NCT04192695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge cell collection device
Description: The Cytosponge™ is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus. Cytosponge™ has excellent safety profile and is approved by the Food and Drug Administration (FDA) and the Healthcare Products Regulatory Agency (HPRA) in the UK.
Study NCT05305729 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05359471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone densitometry
Description: It is the standard method for diagnosing osteoporosis. In the central DXA examination, which measures bone density of the hip and spine, the patient lies on a padded table.
Study NCT05359471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Smoking and drug related questionnaires will be used as variable to see dependence, how it impacts participants activities/health or determining whether they are light/moderate/heavy smoker
Study NCT05359471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Review of medical chart
Description: History of previous liver diseases including hepatitis B, C, and HIV
Study NCT05133115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fostering Resilience in Adolescents at Risk
Description: The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual \& Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support.
Study NCT05550168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser therapy
Description: The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
Study NCT04670120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrifazimine (TBI-166)
Description: The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.
Study NCT04670120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrifazimine (TBI-166)
Description: The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.
Study NCT05502627 — intervention group
Intervention type: DRUG
Intervention: 0.25% lemon grass oil mouthwash
Description: 0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
Study NCT05453851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Undergo pancreatectomy
Study NCT05453851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05453851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Planning
Description: Undergo IV autologous islet cell transplant
Study NCT05589324 — intervention group
Intervention type: BEHAVIORAL
Intervention: 3D-printed writing aids task
Description: Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
Study NCT05767983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free milk
Description: Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
Study NCT05767983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free yogurt
Description: Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
Study NCT05767983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat cheese
Description: Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
Study NCT05767983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice
Description: Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
Study NCT05767983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack skipping
Description: Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
Study NCT05985863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard medical treatment
Description: standard medical treatment for ACLF
Study NCT05985863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard medical treatment
Description: standard medical treatment for ACLF
Study NCT05985863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% human serum albumin in 0.9% saline (at week0, week1 and week2)
Study NCT05985863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)
Study NCT05985863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC_Prolonged
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
Study NCT06182059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous peripheral nerve block
Description: continuous regional anesthesia in total knee replacement
Study NCT06182059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous peripheral nerve block
Description: continuous regional anesthesia in total knee replacement
Study NCT05876325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FINassist Patient
Description: The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
Study NCT05876325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FINassist Caregiver
Description: The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
Study NCT05128838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RISE (Reinvent, Integrate, Strengthen, Expand) Intervention
Description: Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
Study NCT04897386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvalizumab
Description: Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total
Study NCT04882696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-slip socks
Description: Patients will wear non-slip socks during their hospitalization
Study NCT05952076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. infantis Bi-26
Description: A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
Study NCT05952076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
Study NCT05428956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Inhalation technique
Description: Single maximal inhalation with breath hold technique
Study NCT05428956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Inhalation technique
Description: Single maximal inhalation with breath hold technique
Study NCT05428956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal inhalation technique
Description: 5 tidal breaths technique
Study NCT05428956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal inhalation technique
Description: 5 tidal breaths technique
Study NCT05466721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrustoma C3
Description: The participant will use the device for 14 days.
Study NCT05466721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrustoma C3
Description: The participant will use the device for 14 days.
Study NCT05466721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast Alterna
Description: The participant will use the device for 14 days.
Study NCT05466721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Alterna
Description: The participant will use the device for 14 days.
Study NCT04895917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab and pomalidomide
Description: Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
Study NCT01057836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neck endurance training
Study NCT01057836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Study NCT06030206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigator-designed lung transplant education resource (Research Intervention)
Description: Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.
Study NCT06030206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available transplant education resource (Attention-control)
Description: Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
Study NCT05523947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH32367
Description: Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8.~Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll 65 and 40 patients, respectively.
Study NCT05602727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 oral capsule
Study NCT05602727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT05434052 — intervention group
Intervention type: OTHER
Intervention: Turkish Validity and Reliability of The CIQ-R Scale
Description: The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society and to make its validity and reliability in Turkish. It has 18 questions. This study will be conducted with stroke patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
Study NCT04629833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC0518
Description: MC0518 will be intravenously infused immediately after thawing.
Study NCT04629833 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
Study NCT06500468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillSense System
Description: The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected.
Study NCT05786547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Per package dosing, tablet taken orally
Study NCT05786547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free Mobile (PSF-M)
Description: Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
Study NCT05786547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Brief cessation advice plus referral to local tobacco quitline
Study NCT05440851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultra-Protective Ventilation Facilitated by Extracorporeal Support
Description: Patients randomized to the intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Study NCT05440851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lung-Protective Ventilation (LPV)
Description: Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
Study NCT05440851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Driving Pressure-Limited Ventilation (DPL)
Description: Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
Study NCT05440851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)
Description: Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
Study NCT05440851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Early Cohort corticosteroid dose
Description: Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
Study NCT05440851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Extended Cohort corticosteroid dose
Description: Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).